Reviews
Pharmaceutical Aspects of Intranasal Delivery of Vaccines Using Particulate Systems

https://doi.org/10.1002/jps.21493Get rights and content

Abstract

The nasal route offers a promising opportunity for the delivery of vaccines. This review analyses the opportunities and novel delivery strategies based on particulate systems for the nasal delivery of vaccines, including liposomes, proteosomes, virosomes, nano- and microparticulate systems, with and without adjuvants. The influence of pharmaceutical aspects of the particulate formulations on nasal delivery is analysed. Recently developed delivery devices for nasal vaccination are also described. Potential barriers to clinical and commercial success of some novel intranasal vaccines are critically evaluated. Although particulate systems may offer potential in the nasal delivery of vaccines by enhancing uptake by antigen-presenting cells, the real success in enhancement of vaccine delivery can only be achieved by careful design and manipulation of physicochemical properties of particulate vaccine delivery systems.

Section snippets

INTRODUCTION

The continuous emergence of new pathogens and evolution of resistance of micro-organisms towards conventional drugs make it mandatory to continue to develop efficient vaccination strategies capable of producing acquired immune response, which is both antigen specific and possesses memory. The two important aspects of any successful vaccination strategy are to increase the potential to generate a potent defence against diseases that evade the immune system, and to develop long-lasting effective

OPPORTUNITIES AND CHALLENGES IN MUCOSAL VACCINE DELIVERY

Most significant viral and bacterial infections are acquired through the mucosal membranes of the respiratory, intestinal, lachrymal, or urogenital tract.10 Immunization via mucosal routes has been reported to induce both mucosal and systemic immune responses at least in some monogastric species including human,6 hence the potential usefulness of this strategy in the prevention of initial colonization of the mucosa by pathogenic microbes. The antibody-mediated protection at the mucosal surfaces

PHYSIOLOGY OF NASAL TISSUES

NALT, the prime inductive site for nasal mucosal immunity, is arranged on both sides of the nasopharyngeal duct in rodents.21, 22 The collection of oropharyngeal tissue and NALT equivalent tissues is called Waldeyer's ring in humans. The paired tubal tonsils, the paired palatine tonsils, a lingual tonsil, and nasopharyngeal tonsil or adenoids constitute the Waldeyer's ring.23, 24 They are the principal components of the mucosa-associated lymphoid tissue (MALT) of the human pharynx. Antigen

INTRANASAL VACCINE DELIVERY

The intranasal route of administration has an advantage over the oral route in that much lower doses of antigen are required because there is no significant dilution of the vaccine formulations by nasal fluids and no exposure to low pH or a broad range of secreted degradative enzymes.36 In addition, potent responses in the respiratory and genital tracts could be induced by intranasal immunization, as a consequence of the common mucosal immune system.37 The lower antigen dose requirement and

PARTICULATE SYSTEMS FOR INTRANASAL VACCINE DELIVERY

The nasal mucosa is an attractive option for vaccine delivery because of the absence of acidity, lack of abundant secreted enzymes and small mucosal surface area that result in a low dose requirement of antigen.39 The formulation of antigens in various particulate delivery systems for intranasal administration may be advantageous in the following ways: (i) protection of the antigen from mucosal enzymes; (ii) facilitating the preferential uptake of encapsulated antigen by specialized NALT M

PHARMACEUTICAL FACTORS AFFECTING NASAL PARTICULATE VACCINE DELIVERY

Performance of a nasal vaccine can be greatly influenced by the nature of the delivery system deployed and hence their importance is evident in the development of nasal vaccines. The major formulation factors related to nasal delivery of particulate vaccines are reviewed below.

DELIVERY DEVICES FOR INTRANASAL VACCINE ADMINISTRATION

Efficient delivery devices for intranasal administration of vaccines are crucial for the successful development and application of nasal vaccines. Intranasal delivery of vaccines pose two serious challenges: first is accurate and repeated dispensing of very small quantities of formulated vaccine and second is deposition of the formulated vaccine to all areas of the nasal mucosa (especially lymphoid tissues) while limiting the deposition of particles in the lung. Other aspects related to nasal

INDUSTRIAL AND REGULATORY ASPECTS

A small number of nasal vaccine delivery systems are under evaluation at various phases of clinical trials including a cochleate containing intranasal formulation for hepatitis B, a liposomal based intranasal influenza vaccine and a proteosome based formulation incorporating heat-labile E. coli enterotoxin (LTK63) as adjuvant for influenza.210 However, some vaccine products based on particulate delivery systems are licensed globally for the parenteral route of administration, for example,

CONCLUSIONS

The intranasal route of immunization has demonstrated several important advantages over the other routes, including noninvasiveness and the potential for the induction of enhanced immunity in the genitourinary, respiratory and gastrointestinal tracts. The pharmaceutical aspects of nasal immunization are critical for the successful development of nasal vaccines. Particulate delivery systems in combination with novel nasal spray devices can place intranasal immunization as the preferred route of

REFERENCES (249)

  • J.R. McGhee et al.

    The mucosal immune system: From fundamental concepts to vaccine development

    Vaccine

    (1992)
  • G. Dietrich et al.

    Experience with registered mucosal vaccines

    Vaccine

    (2003)
  • T.K.S. Mukkur et al.

    Systemic and mucosal intestinal antibody response of sheep immunized with aromatic-dependent live or killed Salmonella typhimurium

    Comp Immunol Microbiol Infect Dis

    (1995)
  • L. Illum

    Nanoparticulate systems for nasal delivery of drugs: A real improvement over simple systems?

    J Pharm Sci

    (2007)
  • M. Perry et al.

    Immunology of the tonsils

    Immunol Today

    (1998)
  • A. Gebert et al.

    M cells at locations outside the gut

    Semin Immunol

    (1999)
  • S.S. Davis

    Nasal vaccines

    Adv Drug Del Rev

    (2001)
  • G. Kallenius et al.

    Should a new tuberculosis vaccine be administered intranasally?

    Tuberculosis

    (2007)
  • P. Brandtzaeg et al.

    Let's go mucosal: Communication on slippery ground

    Trends Immunol

    (2004)
  • P. Brandtzaeg

    Induction of secretory immunity and memory at mucosal surfaces

    Vaccine

    (2007)
  • P. Brandtzaeg et al.

    Regional specialization in the mucosal immune system: What happens in the microcompartments?

    Immunol Today

    (1999)
  • M. Vajdy et al.

    Microparticles for intranasal immunization

    Adv Drug Del Rev

    (2001)
  • M.T. De Magistris

    Mucosal delivery of vaccine antigens and its advantages in pediatrics

    Adv Drug Del Rev

    (2006)
  • M. Singh et al.

    A novel bioadhesive intranasal delivery system for inactivated influenza vaccines

    J Control Release

    (2001)
  • A. des Rieux et al.

    Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach

    J Control Release

    (2006)
  • A. Jegerlehner et al.

    A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses

    Vaccine

    (2002)
  • R.L. Owen

    Sequential uptake of horseradish peroxidase by lymphoid follicle epithelium of Peyer's patches in the normal unobstructed mouse intestine: An ultrastructural study

    Gastroenterol

    (1977)
  • G. Kallenius et al.

    Should a new tuberculosis vaccine be administered intranasally?

    Tuberculosis

    (2007)
  • C. Locht et al.

    Bordetella pertussis from functional genomics to intranasal vaccination

    Int J Med Microbiol

    (2004)
  • A.M. Carcaboso et al.

    Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles

    Vaccine

    (2004)
  • A. Vila et al.

    PLA-PEG particles as nasal protein carriers: The influence of the particle size

    Int J Pharm

    (2005)
  • A. Vila et al.

    Design of biodegradable particles for protein delivery

    J Control Release

    (2002)
  • D.H. Jones et al.

    Poly(-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration

    Vaccine

    (1997)
  • J.E. Eyles et al.

    Microsphere translocation and immunopotentiation in systemic tissues following intranasal administration

    Vaccine

    (2001)
  • J.E. Eyles et al.

    Immunological responses to nasal delivery of free and encapsulated tetanus toxoid: Studies on the effect of vehicle volume

    Int J Pharm

    (1999)
  • Y. Men et al.

    Induction of a cytotoxic T lymphocyte response by immunization with a malaria specific CTL peptide entrapped in biodegradable polymer microspheres

    Vaccine

    (1997)
  • T. Storni et al.

    Immunity in response to particulate antigen-delivery systems

    Adv Drug Del Rev

    (2005)
  • A. Moore et al.

    Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells

    Vaccine

    (1995)
  • A.G. Coombes et al.

    Resorbable lamellar particles of polylactide as adjuvants for influenza virus vaccines

    Biomaterials

    (1998)
  • I. Jabbal-Gill et al.

    Polymeric lamellar substrate particles for intranasal vaccination

    Adv Drug Del Rev

    (2001)
  • M. Higaki et al.

    Enhancement of immune response to intranasal influenza HA vaccine by microparticle resin

    Vaccine

    (1998)
  • A.K. Andrianov et al.

    Preparation of hydrogel microspheres by coacervation of aqueous polyphosphazene solutions

    Biomaterials

    (1998)
  • R.J. Soane et al.

    Evaluation of the clearance characteristics of bioadhesive systems in humans

    Int J Pharm

    (1999)
  • L. Illum et al.

    Chitosan as a novel nasal delivery system for vaccines

    Adv Drug Deliv Rev

    (2001)
  • I.M. van der Lubben et al.

    Chitosan and its derivatives in mucosal drug and vaccine delivery

    Euro J Pharm Sci

    (2001)
  • I.M. van der Lubben et al.

    Chitosan for mucosal vaccination

    Adv Drug Del Rev

    (2001)
  • M. Amidi et al.

    N-Trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: Biological properties and immunogenicity in a mouse model

    Vaccine

    (2007)
  • R.J. Soane et al.

    Clearance characteristics of chitosan based formulations in the sheep nasal cavity

    Int J Pharm

    (2001)
  • A. Vila et al.

    Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice

    Euro J Pharm Biopharm

    (2004)
  • M.M. Issa et al.

    Targeted gene delivery with trisaccharide-substituted chitosan oligomers in vitro and after lung administration in vivo

    J Control Release

    (2006)
  • Cited by (0)

    View full text